Literature DB >> 31699387

New quinoline-2-one/pyrazole derivatives; design, synthesis, molecular docking, anti-apoptotic evaluation, and caspase-3 inhibition assay.

Ashraf A Aly1, Samia M Sayed2, El-Shimaa M N Abdelhafez3, Sara Mohamed Naguib Abdelhafez4, Walaa Yehia Abdelzaher5, Mohamed A Raslan6, Amira E Ahmed7, Khaled Thabet8, Ahmed A M El-Reedy9, Alan B Brown10, Stefan Bräse11.   

Abstract

We report the synthesis of new quinoline-2-one/pyrazole hybrids and their antiapoptotic activity. This effect was studied in sight of decreasing tissue damage induced by I/R in colon of rats using N-acetylcysteine (NAC) as anti-apoptotic reference. Compounds 6a, 6c and 6f showed significant improvement for oxidative stress parameters MDA, SOD, GSH and NOx in comparison with model group and greater than the reference NAC (N-acetylcysteine), whereas compounds 6d and 6e exhibited weaker antioxidant activity when compared with the reference NAC. Moreover, compounds 6a, 6c and 6f showed significant decrease in inflammatory mediators TNFα and CRB greater than NAC when compared to the model group especially compound 6c whose found CRB conc 1.90 (mg/dL) in comparison to NAC of conc 2.13 mg/dL. Additionally, colonic histopathological investigation was performed to all targeted compounds that indicates H&E sections of compounds 6a and 6f revealed apparent normal colonic cells while compound 6e showed dilated blood vessels with more apoptotic cells if compared with NAC. Caspase-3 inhibition assay revealed that compounds 6a, 6b and 6d weaken caspase-3 expression to an extent higher than NAC (1.063, 0.430, 0.731 and 1.115, respectively). Docking studies with caspase-3 revealed that most of the tested compounds showed good binding with the enzyme especially for compound 6d make several interactions better than that of the reference NAC.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-apoptotic quinoline; Antioxidant; Caspase-3; Colon; Docking; Histopathology; NAC; Pyrazole

Mesh:

Substances:

Year:  2019        PMID: 31699387     DOI: 10.1016/j.bioorg.2019.103348

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  5 in total

1.  Design, Synthesis, and Molecular Docking of Paracyclophanyl-Thiazole Hybrids as Novel CDK1 Inhibitors and Apoptosis Inducing Anti-Melanoma Agents.

Authors:  Ashraf A Aly; Stefan Bräse; Alaa A Hassan; Nasr K Mohamed; Lamiaa E Abd El-Haleem; Martin Nieger; Nesrin M Morsy; Mohammed B Alshammari; Mahmoud A A Ibrahim; Elshimaa M N Abdelhafez
Journal:  Molecules       Date:  2020-11-27       Impact factor: 4.411

2.  Autoxidation of 4-Hydrazinylquinolin-2(1H)-one; Synthesis of Pyridazino[4,3-c:5,6-c']diquinoline-6,7(5H,8H)-diones.

Authors:  Sara M Mostafa; Ashraf A Aly; Alaa A Hassan; Esraa M Osman; Stefan Bräse; Martin Nieger; Mahmoud A A Ibrahim; Asmaa H Mohamed
Journal:  Molecules       Date:  2022-03-25       Impact factor: 4.411

3.  Synthesis, Characterization, and In Vivo Study of Some Novel 3,4,5-Trimethoxybenzylidene-hydrazinecarbothioamides and Thiadiazoles as Anti-Apoptotic Caspase-3 Inhibitors.

Authors:  Sara M Mostafa; Ashraf A Aly; Stefan Bräse; Martin Nieger; Sara Mohamed Naguib Abdelhafez; Walaa Yehia Abdelzaher; El-Shimaa M N Abdelhafez
Journal:  Molecules       Date:  2022-03-31       Impact factor: 4.927

4.  The Antioxidant Carrichtera annua DC. Ethanolic Extract Counteracts Cisplatin Triggered Hepatic and Renal Toxicities.

Authors:  Enas E Eltamany; Sameh S Elhady; Mohamed S Nafie; Haidy A Ahmed; Dina M Abo-Elmatty; Safwat A Ahmed; Jihan M Badr; Asmaa R Abdel-Hamed
Journal:  Antioxidants (Basel)       Date:  2021-05-21

5.  Design, Synthesis, Molecular Docking, Antiapoptotic and Caspase-3 Inhibition of New 1,2,3-Triazole/Bis-2(1H)-Quinolinone Hybrids.

Authors:  Essmat M El-Sheref; Ashraf A Aly; Mohammed B Alshammari; Alan B Brown; Sara Mohamed Naguib Abdel-Hafez; Walaa Yehia Abdelzaher; Stefan Bräse; ElShimaa M N Abdelhafez
Journal:  Molecules       Date:  2020-10-30       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.